Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma

• Status: Terminated
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the safety and efficacy of QAV680 in patients with mild to moderate asthma

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals

Criteria

Inclusion Criteria:

• Patients with moderate persistent asthma

Exclusion Criteria:

• Smokers

• Any significant disease or illness, other than asthma

Other protocol-defined inclusion/exclusion criteria may apply